Release Date: 07-Aug-2014
Global Orphan Drug Market Report Highlights:
Though the developmental costs are very high, the potential to earn significant profits certainly outweigh such high costs. As an illustration, in 2010, Soliris, which is used to treat paroxysymal nocturnal hemoglobinuria, a rare life-threatening blood disease was the most expensive drug in the USA in 2012 costing more than $440,000 annually. The developer of this drug, Alexion Pharmaceuticals, earned a total revenue of USD 1.134 billion in sales. Given that the target population is only 4,000 to 6,000 people, the revenue earned by Soliris shows the immense potential that this industry holds for the future.
Additionally, the repositioning of orphan drugs as treatment to other rare diseases can increase the sales volumes. It has been observed that close to 15 percent of the drugs had subsequent launches for other rare illnesses. Also, it was observed that among the top 10 orphan drugs, six had more than one rare disease indication with a peak value averaging USD 34.3 billion in overall sales potential, compared with USD 8.1 billion for drugs with only one such indication.
For Report Sample Visit: Global Orphan Drug Market Outlook 2018
Or Contact: firstname.lastname@example.org